Genotype-to-Trial Matching Automation Using Variant Data

This workflow automates the most critical bottleneck in precision oncology: identifying trial-ready patients from fragmented genomic and clinical data. It ingests variant call format (VCF) files from sequencing labs, annotates them against trial registries like ClinicalTrials.gov, and triggers notifications when a match is found. The operational upside is direct: reducing patient-finding time from weeks to minutes, increasing site activation throughput, and improving enrollment rates for biomarker-driven studies by systematically surfacing eligible candidates that manual processes miss.

Implementation requires orchestrating agents for variant annotation (using ClinVar, dbSNP), integrating with EMRs for patient context, and building a rules engine that interprets complex trial eligibility beyond simple biomarker presence. Controls are essential: all high-stakes matches require oncologist sign-off via integrated review dashboards, and every automated decision is logged with full traceability for regulatory audit. The architecture typically uses LangGraph for agent coordination, integrates with Epic or Cerner via FHIR, and deploys within the sponsor or CRO's secure cloud to maintain PHI governance.

This architecture automates the high-cost, low-throughput process of manually comparing patient variant data against trial biomarker criteria. It directly reduces enrollment cycle times from months to days, improving site utilization and accelerating time-to-data for sponsors. The operational upside comes from continuous, automated screening of streaming genomic data against a dynamic registry of trial protocols, ensuring no eligible patient is missed due to human bandwidth or data fragmentation across labs and EHRs.

Implementation integrates with genomic pipelines (Illumina DRAGEN, SOPHiA DDM) and trial registries (ClinicalTrials.gov, internal CTMS) via API agents. The matching engine uses rule-based logic from protocol synopses and NLP-extracted criteria. Critical controls include an MD-in-the-loop review gate for borderline matches, continuous bias monitoring in scoring algorithms, and full audit trails for regulatory inspection. Deployment is typically containerized, with observability built into each agent's decision path.

Phase 1 establishes a foundational pipeline for ingesting and annotating genomic variant data from lab feeds (e.g., VCF files) and integrating with a single trial registry like ClinicalTrials.gov. This initial, contained workflow focuses on generating high-confidence patient-trial matches for a single precision oncology study. The goal is to validate the core matching logic, data quality, and notification system, delivering a measurable reduction in manual screening time for the pilot study team within 90 days.

Phase 2 integrates the validated core engine with enterprise EHR systems (Epic, Cerner) via FHIR APIs and implements privacy-preserving record linkage to match variant data to patient identities. This phase enables multi-protocol screening and introduces physician review queues within existing clinical workflows. Phase 3 focuses on scaling and governance, adding integrations with CTMS and EDC platforms, implementing continuous bias detection and audit trail generation, and rolling out the automated matching workflow across the full therapeutic portfolio.

The business value of automating genotype-to-trial matching is clear: it collapses biomarker study enrollment from months to days. However, the operational risk is equally high. A production workflow must embed controls at every layer—from variant annotation accuracy and consent verification to physician review gates—to prevent misdirected patient outreach or protocol violations. This requires integrating directly with lab information systems (LIS), genomic data repositories like ClinVar, and EHRs such as Epic or Cerner, while maintaining a complete, immutable audit trail of all matching logic and data accesses for regulatory scrutiny.

Implementation follows a phased, risk-gated rollout. Phase 1 targets a single biomarker for a non-interventional registry, deploying the matching logic in a monitored sandbox with 100% human-in-the-loop verification. Success metrics focus on precision and recall against manual screening. Phase 2 expands to a defined set of oncology biomarkers, introducing automated notifications but retaining a mandatory 24-hour review window. Final phase deployment automates full matching and notification for pre-approved, high-confidence scenarios, with continuous monitoring for drift in data quality or algorithm performance, ensuring the system scales without compromising safety or compliance.